Inventor · disambiguated record
Curt W. Bradshaw
Also filed as: BRADSHAW CURT · BRADSHAW CURT W · BRADSHAW CURT WILLIAM
16 granted patents·20 pending applications·370 citations·filing 1992–2025
93Inventor score
Files withSIRIUS THERAPEUTICS INC10TALLAC THERAPEUTICS INC7BRADSHAW CURT W4COVX TECHNOLOGIES IRELAND LTD3SCRIPPS RESEARCH INST3
Top patents by PatentIndex Score
36 records- 0196US5342767ALactobacillus kefir alcohol dehydrogenaseSCRIPPS RESEARCH INST·Filed 1993·Granted Aug 30, 1994·105 cites·6 claims
- 0296US5225339ALactobacillus kefir alcohol dehydrogenaseSCRIPPS RESEARCH INST·Filed 1992·Granted Jul 6, 1993·104 cites·21 claims
- 0395US5385833APseudomonas sp. ATCC No. 49794 alcohol dehydrogenaseSCRIPPS RESEARCH INST·Filed 1992·Granted Jan 31, 1995·81 cites·12 claims
- 0489US11795463B2Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·16 claims
- 0587US8741291B2Multifunctional antibody conjugatesBHAT ABHIJIT SURESH·Filed 2011·Granted Jun 3, 2014·37 cites·42 claims
- 0687US7521425B2Anti-angiogenic compoundsCOVX TECHNOLOGIES IRELAND LTD·Filed 2006·Granted Apr 21, 2009·22 cites·12 claims
- 0785US11920136B2Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2021·Granted Mar 5, 2024·1 cites·47 claims
- 0884US11203611B2Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their useSOLSTICE BIOLOGICS LTD·Filed 2018·Granted Dec 21, 2021·5 cites·35 claims
- 0981US11981703B2Polynucleotide constructsSIRIUS THERAPEUTICS INC·Filed 2017·Granted May 14, 2024·2 cites·13 claims
- 1081US11597744B2Chiral phosphoramidite auxiliaries and methods of their useSIRIUS THERAPEUTICS INC·Filed 2018·Granted Mar 7, 2023·2 cites·20 claims
- 1179US8288349B2Anti-angiogenic compoundsBRADSHAW CURT WILLIAM·Filed 2007·Granted Oct 16, 2012·7 cites·29 claims
- 1279US2024191242A1Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1378US2024287528A1Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1474US2024247025A1Polynucleotide constructsSIRIUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1573US12269839B2Chiral phosphoramidite auxiliaries and methods of their useSIRIUS THERAPEUTICS INC·Filed 2023·Granted Apr 8, 2025·0 cites·13 claims
- 1672US8293714B2Anti-angiogenic compoundsDOPPALAPUDI VENKATA RAMANA·Filed 2009·Granted Oct 23, 2012·2 cites·33 claims
- 1769US2024271143A1Polynucleic acid molecules targeting pcsk9 and uses thereofSIRIUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1866US12351598B2Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their useTALLAC THERAPEUTICS INC·Filed 2021·Granted Jul 8, 2025·0 cites·44 claims
- 1965US8937048B2Anti-angiogenic compoundsDOPPALAPUDI VENKATA RAMANA·Filed 2012·Granted Jan 20, 2015·1 cites·22 claims
- 2058US2025333738A1Polynucleic acid molecules for inhibiting expression of angptl3, pharmaceutical compositions, and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2156US2025361508A1Polynucleic acid molecules targeting agt and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2254US2015057431A1Compositions for treating a disease or condition associated with abnormal angiogenesisCOVX TECHNOLOGIES IRELAND LTD·Filed 2014·Application pending·0 cites
- 2353US2020392498A1Polynucleotide constructs having bioreversible and non-bioreversible groupsSOLSTICE BIOLOGICS LTD·Filed 2020·Application pending·0 cites
- 2453US2023364255A1Transglutaminase-mediated conjugationTALLAC THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2550US2025250573A1Polynucleic acid molecules for inhibiting expression of fxi, pharmaceutical compositions, and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2649US2014335192A1Delivery of rna interfering agentsKIPPERMAN RM CH 7 BK TRUSTEE FOR TRAVERSA THERAP·Filed 2014·Application pending·0 cites
- 2748US2025188465A1Polynucleic acid molecules targeting apoc3 and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2848US2025188464A1Polynucleic acid molecules for inhibiting expression of lp(a), pharmaceutical compositions, and uses thereofSIRIUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2948US2022096649A1Immunomodulating polynucleotide conjugates and methods of useTALLAC THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3047US8912148B2Methods of treating a disease or condition associated with abnormal angiogenesisBRADSHAW CURT·Filed 2012·Granted Dec 16, 2014·0 cites·24 claims
- 3146US2009098130A1Glucagon-like protein-1 receptor (glp-1r) agonist compoundsBRADSHAW CURT W·Filed 2008·Application pending·0 cites
- 3243US2016257961A1Polynucleotide constructs having disulfide groupsBRADSHAW CURT W·Filed 2014·Application pending·0 cites
- 3343US2017114341A1Polynucleotide constructs having bioreversible and non-bioreversible groupsBRADSHAW CURT W·Filed 2015·Application pending·0 cites
- 3440US2011087010A1Anti-angiogenic compoundsCOVX TECHNOLOGIES IRELAND LTD·Filed 2010·Application pending·0 cites
- 3539US2019194655A1Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioateBRADSHAW CURT W·Filed 2016·Application pending·0 cites
- 3628US2018346505A1Mononucleotides having a bioreversible disulfide groupSOLSTICE BIOLOGICS LTD·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Curt W. Bradshaw files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →